Comparing to previous quarter (Q4 is always Seasonally strong and Q1 is always weak), Axiron dropped 17%, but Androgel dropped sharp 40%.
With both main products are facing competition from generic drugs, it seems Axiron may maintain or even increases the market share but Androgel lost a lots.
The figure will show Axiron' market share likely above 14% at the worst.
$39.1m is not a rally, but further convinced sales stabilizing and FDA' impact is fading.
- Forums
- ASX - By Stock
- ACR
- Axiron/androgel sales over last quarter.
ACR
acrux limited
Add to My Watchlist
5.88%
!
1.6¢

Axiron/androgel sales over last quarter.
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
1.6¢ |
Change
-0.001(5.88%) |
Mkt cap ! $6.524M |
Open | High | Low | Value | Volume |
1.6¢ | 1.7¢ | 1.6¢ | $839 | 50.35K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 1043634 | 1.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.7¢ | 157783 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
7 | 1043634 | 0.016 |
7 | 1309314 | 0.015 |
3 | 420000 | 0.014 |
2 | 397000 | 0.013 |
1 | 80000 | 0.012 |
Price($) | Vol. | No. |
---|---|---|
0.017 | 157783 | 2 |
0.018 | 252359 | 2 |
0.019 | 682161 | 4 |
0.020 | 50000 | 1 |
0.021 | 203466 | 1 |
Last trade - 13.07pm 30/06/2025 (20 minute delay) ? |
Featured News
ACR (ASX) Chart |